Editorial note: CMS published the Contract Year 2027 Medicare Advantage and Part D proposed rule in November 2025. The agency subsequently issued the final rule on April 2, 2026, followed by the final 2027 Medicare Advantage payment announcement on April 6. This article explains the original proposal, identifies important final decisions, and offers practical predictions for the 2027 market.
CMS regulations are rarely mistaken for light vacation reading. Still, the agency’s Contract Year 2027 rule deserves attention because it reaches into nearly every important corner of Medicare Advantage and Medicare Part D: quality bonuses, prescription drug costs, enrollment rights, supplemental benefits, marketing practices, risk adjustment, and plan administration.
“`
The proposal’s central theme was simplification. CMS sought to remove quality measures that no longer produced meaningful differences among plans, codify major prescription drug reforms already operating under the Inflation Reduction Act, and eliminate requirements the agency considered duplicative or burdensome. At the same time, CMS asked broader questions about the future of Medicare Advantage, including whether its payment and quality systems still reward the right behavior.
That combination makes the rule more than a routine annual tune-up. It is part maintenance manual, part policy compass, and part warning that future Medicare Advantage reforms may be considerably more ambitious.
“`
First, Understand Which CMS Document Does What
“`
The 2027 policy cycle produced several documents that are easy to mix together. Unfortunately, CMS did not design the process for people who enjoy having only one spreadsheet open.
The proposed and final policy rules
The Medicare Advantage and Part D proposed rule addressed program operations, Star Ratings, enrollment, benefit administration, consumer protections, marketing, and regulatory requirements. CMS published the proposal in November 2025 and accepted public comments before issuing the final rule in April 2026.
The Advance Notice and Rate Announcement
The Advance Notice separately proposed payment methodology changes, including growth rates, risk adjustment, normalization, and acceptable sources of diagnoses. The January 2026 Advance Notice estimated that average Medicare Advantage payments would increase by only 0.09% for 2027.
The final Rate Announcement was much more favorable to insurers. CMS projected an average 2.48% year-over-year payment increase, representing more than $13 billion in additional Medicare Advantage payments. CMS also estimated that ordinary growth in plan risk scores could add approximately 2.50%, producing a combined projected revenue change of roughly 4.98% before individual plan circumstances are considered.
In other words, the policy rule explains how the game is played. The Rate Announcement helps determine how much money is on the field.
“`
Major Component One: A Leaner Star Ratings System
“`
Star Ratings are not decorative gold stickers. They help beneficiaries compare plans and can determine whether a Medicare Advantage contract receives valuable quality bonus payments and larger rebates. Those funds can support lower premiums, reduced cost sharing, supplemental benefits, or healthier plan margins.
The proposed rule called for removing 12 measures beginning with the 2027 measurement year. CMS argued that several measures focused heavily on administrative processes or showed so little variation that they no longer helped beneficiaries distinguish one plan from another.
The proposed removals included measures involving appeals, customer service, complaints, call-center accessibility, member departures, diabetes eye exams, statin therapy, Medicare Plan Finder price accuracy, and ratings of healthcare quality. After reviewing comments, CMS finalized the removal of 11 measures rather than all 12.
The Health Equity Index reversal
CMS also declined to implement the Excellent Health Outcomes for All reward, formerly known as the Health Equity Index reward, for the 2027 Star Ratings. Instead, the agency retained the historical reward factor, which favors contracts that perform consistently well across multiple measures.
This decision could redistribute quality bonus payments. Plans that had invested heavily in the anticipated health-equity methodology may need to recalibrate their strategies, while consistently high-performing contracts may benefit from retaining the familiar reward system.
A new behavioral health measure
CMS added a Part C Depression Screening and Follow-Up measure beginning with the 2027 measurement year and affecting the 2029 Star Ratings. This change signals that behavioral health will remain a growing quality priority even as the overall measure inventory becomes smaller.
The practical message is simple: fewer measures do not necessarily mean easier performance management. When CMS removes weaker signals, the surviving clinical and outcome measures become more important.
“`
Major Component Two: Permanent Part D Redesign
“`
The Inflation Reduction Act dramatically redesigned Medicare Part D beginning in 2025. CMS initially implemented many changes through temporary program instructions. Because that special implementation authority expires after 2026, the 2027 rule moves those policies into permanent regulations.
The codified structure includes:
- Elimination of the old coverage-gap phase, commonly called the donut hole.
- An inflation-adjusted annual out-of-pocket spending threshold.
- No additional beneficiary cost sharing after reaching the catastrophic phase.
- Revised financial responsibility among plans, manufacturers, Medicare, and beneficiaries.
- Permanent operation of the Manufacturer Discount Program.
- Updated true out-of-pocket, specialty-tier, reinsurance, and selected-drug subsidy rules.
For beneficiaries, the redesigned benefit offers stronger protection against catastrophic prescription drug expenses. For plan sponsors, however, it increases financial exposure and makes formulary strategy, manufacturer negotiations, utilization forecasting, and pharmacy operations even more important.
A plan can no longer treat Part D as a quiet passenger in the back seat. Under the redesigned benefit, Part D is holding the map and commenting on every turn.
“`
Major Component Three: Enrollment and Provider Network Changes
“`
The proposed rule sought to broaden a Special Enrollment Period for Medicare Advantage members affected when a provider or facility leaves a plan’s network. Under the proposal, an enrollee would not have needed CMS or the plan to determine that the network change was “significant” before qualifying for an opportunity to change coverage.
The proposal also contemplated clearer notices explaining the enrollment period, its deadlines, other election opportunities, and potential Medigap rights.
CMS did not finalize the expanded provider-termination Special Enrollment Period. The final rule did, however, clarify that certain exceptional Special Enrollment Periods require prior CMS approval.
This outcome illustrates a recurring tension. Beneficiaries want continuity with trusted physicians, while plans need the ability to manage changing provider networks. CMS may revisit the issue because midyear provider terminations remain one of the most disruptive experiences a member can face.
“`
Major Component Four: Supplemental Benefits and SSBCI Controls
“`
Medicare Advantage plans increasingly compete through dental, vision, hearing, transportation, food, utility, and other supplemental benefits. Special Supplemental Benefits for the Chronically Ill, or SSBCI, have become especially important in Special Needs Plans.
The final rule requires plans to use objective criteria rather than simple self-attestation when determining SSBCI eligibility. Plans must also publicly describe their eligibility criteria. When benefits are administered through debit or flex cards, plans must clearly disclose eligible items and conditions and maintain an alternative reimbursement process when a card fails.
CMS also clarified that cannabis products illegal under applicable federal or state law cannot be offered as SSBCI. Certain legally compliant hemp-seed food ingredients may remain permissible when they otherwise satisfy benefit requirements.
The broader lesson is that attractive benefit advertising must be supported by functional administration. A $100 allowance is not particularly impressive when the card is declined, the store is excluded, and nobody can explain why.
“`
Major Component Five: Deregulation and Marketing Changes
“`
CMS framed several proposals as regulatory relief. Finalized changes include eliminating the requirement for Medicare Advantage plans to mail midyear notices identifying unused supplemental benefits and removing specific health-equity requirements from quality improvement programs and utilization management committees.
Plans are no longer required under these provisions to appoint a health-equity expert to the utilization management committee, complete the specified annual health-equity analysis, or publicly post that analysis. CMS also reduced certain LI NET call-center obligations and exempted some account-based coverage arrangements from creditable-coverage disclosure requirements.
Marketing rules were loosened as well. CMS removed restrictions affecting the timing and manner of conversations between beneficiaries and licensed agents or brokers and modified requirements for third-party marketing organizations.
Supporters argue that these changes eliminate paperwork and allow beneficiaries to speak with agents when they choose. Critics worry that fewer guardrails could encourage aggressive marketing, confusing claims, or enrollment decisions based on flashy extras rather than provider access, drug coverage, and total costs.
Expect marketing oversight to become more data-driven. CMS may impose fewer universal procedural rules while relying more heavily on complaint trends, recorded calls, rapid enforcement, and targeted audits.
“`
Major Component Six: Future Risk Adjustment Reform
“`
Some of the most consequential material in the proposed rule appeared in Requests for Information rather than binding regulations. CMS asked whether the Medicare Advantage risk-adjustment system unintentionally favors large, established organizations with sophisticated coding operations.
The agency explored concepts such as artificial intelligence, alternative data, improved payment accuracy, revised quality bonuses, and a shorter delay between quality measurement and financial rewards.
Separately, the 2027 payment process finalized restrictions on diagnoses from unlinked chart reviews and audio-only services. CMS did not implement the proposed new risk model for 2027, choosing instead to continue the 2024 CMS-HCC model while the market adjusts.
This pause should not be mistaken for abandonment. Risk adjustment remains one of the most financially important and politically controversial parts of Medicare Advantage. Plans should expect future pressure to prove that diagnoses are connected to genuine clinical encounters and meaningful care management.
“`
Major Component Seven: Special Needs Plans and Integrated Care
“`
Special Needs Plans are driving a large share of Medicare Advantage enrollment growth. CMS expressed particular concern about beneficiaries who qualify for both Medicare and Medicaid enrolling in chronic condition or institutional Special Needs Plans rather than Dual Eligible Special Needs Plans designed to coordinate both programs.
The agency requested feedback on whether C-SNPs or I-SNPs with large numbers of dual-eligible members should face state contracting requirements similar to D-SNPs.
No sweeping policy was finalized, but the direction is clear. Future CMS rules are likely to demand stronger evidence that Special Needs Plans actually integrate care, reduce fragmentation, and help members navigate Medicare and Medicaid rather than merely placing a specialized label on an insurance card.
“`
Predictions for Medicare Advantage and Part D in 2027
“`
1. Supplemental benefits will be redesigned, not simply expanded
Despite the improved final payment rate, insurers continue to face elevated medical utilization and cost pressure. Some plans may reduce flexible allowances, narrow dental networks, tighten eligibility for food or utility benefits, or withdraw from less profitable counties. Benefits that remain are likely to receive closer return-on-investment scrutiny.
2. Star Ratings strategy will shift toward fewer, heavier priorities
Plans will move staff and vendor resources away from deleted measures and toward high-weight clinical outcomes, medication adherence, member experience, and behavioral health. Organizations near the four-star bonus threshold will model every change with the enthusiasm of accountants discovering a new pivot table.
3. Diagnosis documentation will become more encounter-centered
The exclusion of unlinked chart-review diagnoses will encourage plans and providers to capture conditions during legitimate visits, connect documentation to active assessment and treatment, and improve encounter-data completeness.
4. Marketing activity may increase
Relaxed procedural requirements could make agent interactions faster and more frequent. That may help beneficiaries obtain assistance, but it also increases the importance of monitoring misleading superlatives, incomplete plan comparisons, and exaggerated descriptions of flex-card benefits.
5. CMS will return to broader payment reform
The agency’s requests for information suggest that future rules may test new risk-adjustment methods, alter quality bonus incentives, use alternative data, or shorten the quality-payment timeline. The 2027 rule is therefore better viewed as a bridge than a final destination.
6. Nutrition and well-being benefits will face an evidence test
CMS has shown interest in nutrition, social connection, emotional well-being, and preventive care. Future models may reward plans for offering these services, but plans will increasingly be expected to demonstrate measurable health outcomes rather than simply report how many grocery cards were distributed.
“`
Practical Experience: Lessons From Implementing Major CMS Rule Changes
“`
Organizations that have worked through previous CMS rule cycles generally learn the same lesson: the regulation is only the beginning. The most difficult work begins when legal language must be converted into benefit designs, call-center scripts, provider instructions, pharmacy edits, marketing reviews, data fields, and member notices.
Start with a provision-by-provision decision log
A common implementation mistake is creating one enormous summary and assuming every department will interpret it the same way. They will not. Compliance may see a disclosure obligation, operations may see a system change, finance may see a bid assumption, and marketing may see three forbidden adjectives.
A stronger approach uses a decision log that identifies each proposed provision, its final status, effective date, responsible department, system impact, member impact, financial impact, and unresolved guidance questions. This becomes especially important when the final rule includes policies carried over from an earlier rulemaking cycle.
Do not confuse regulatory permission with operational readiness
Suppose CMS allows a broader conversation between a beneficiary and an agent. That does not mean every script, recording process, lead source, or downstream marketing partner is suddenly safe. Plans still need controls for accuracy, suitability, documentation, privacy, and complaint handling.
The same principle applies to supplemental benefits. A benefit may be legally permissible but operationally disastrous when vendor networks are incomplete or eligibility data arrive late. Experienced teams test the member journey from beginning to end: advertisement, enrollment, eligibility determination, card activation, purchase attempt, denial, appeal, reimbursement, and complaint resolution.
Model multiple financial scenarios
The movement from a proposed 0.09% payment increase to a final 2.48% increase demonstrates why plans should avoid building one financial forecast and naming it “final_final_really_final.xlsx.” Effective growth rates, normalization, risk-model decisions, Star Ratings, coding trends, and county benchmarks can all change the result.
Practical forecasting usually includes conservative, expected, and favorable scenarios. Each scenario should show what happens to premiums, supplemental benefits, provider contracts, service areas, and capital requirements. A national average payment increase does not guarantee that every contract or county receives the same result.
Keep beneficiary experience visible
Rule implementation can become an exercise in satisfying technical requirements while missing the person trying to fill a prescription or find a specialist. Strong teams therefore track member-facing indicators during implementation: rejected pharmacy claims, call abandonment, complaint categories, prior authorization delays, flex-card failures, network disruptions, and disenrollment inquiries.
For example, a perfectly coded Part D transaction is not a success if the beneficiary leaves the pharmacy without medication because nobody could explain the cost. Likewise, a supplemental benefit is not valuable merely because it appears in the Evidence of Coverage. It must be understandable and usable.
Treat predictions as planning tools, not prophecies
The best regulatory predictions identify decisions that remain sensible under several outcomes. Improving encounter-data accuracy is worthwhile whether CMS changes the risk model next year or three years from now. Strengthening vendor oversight is useful whether marketing rules become stricter or looser. Measuring the clinical value of nutrition benefits is prudent whether CMS launches a formal model or simply increases reporting expectations.
That is the most durable experience-based lesson from the CMS 2027 rule: prepare for the finalized requirements, but build capabilities for the direction of travel. Regulations change annually. Reliable data, clear accountability, responsive member service, and benefits that work outside a PowerPoint presentation remain useful in every contract year.
“`
Conclusion
“`
CMS’ 2027 Medicare Advantage and Part D rule combines quality-measure simplification, permanent Part D reforms, supplemental-benefit controls, enrollment policies, marketing deregulation, and early signals of future payment reform. Some highly visible proposals changed before finalization, including the number of deleted Star measures and the provider-termination Special Enrollment Period. The payment outlook also improved substantially between the Advance Notice and the final Rate Announcement.
For plans, the immediate priorities are bid accuracy, Star Ratings recalibration, Part D readiness, encounter-linked diagnosis documentation, vendor oversight, and realistic supplemental-benefit design. For beneficiaries, the most important task will be comparing total costs, drug coverage, provider networks, and benefit restrictions rather than relying on premiums or advertising alone.
The 2027 rule may simplify several requirements, but it does not simplify the central challenge: delivering affordable, understandable coverage while protecting both patients and taxpayers. CMS has merely rearranged the chessboard. The next round of risk adjustment, quality bonus, and Special Needs Plan reforms is already visible on the horizon.
“`
